RedPath Integrated Pathology

RedPath Integrated Pathology is a molecular diagnostics laboratory headquartered in Pittsburgh, Pennsylvania. The company employs 22 individuals and generates an annual revenue of $8.8 million. RedPath specializes in providing innovative solutions for clinicians through its patented PathFinderTG® platform. This platform analyzes mutational profiles to assist physicians in diagnosing complex cases involving patients at risk of cancer. RedPath conducts all clinical testing and research and development within its state-of-the-art, CLIA-certified, and CAP-accredited laboratory. The PathFinderTG® platform is underpinned by over two decades of scientific and clinical research, with studies based on it published in over 200 peer-reviewed journals, including the prestigious New England Journal of Medicine. Notably, recent healthcare economic studies have demonstrated that utilizing PathFinderTG significantly reduces healthcare costs. Driven by the robust clinical data supporting its platform, RedPath has received favorable coverage decisions from Medicare and several private health insurance providers. For further information or inquiries, please visit RedPath's website at redpathip.com.